Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

Neoplasms Clinical Trial

Official title:

Phase I, Open Label Safety, Pharmacokinetic, and Pharmacodynamic Dose Escalation/De-escalation Study of 852A Administered Intravenously to Subjects With Refractory Solid Organ Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00095160
• Other study ID #: 2003LS039
• Secondary ID: 1493-852A
• Status: Completed
• Phase: Phase 1
• First received: November 1, 2004
• Last updated: November 27, 2017
• Start date: October 2003
• Est. completion date: January 2006

Study information

• Verified date: November 2017
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study 1493-852A is a phase 1 study with the primary objective of determining safety and the highest tolerated dose of an experimental immune response modifier administered intravenously to patients with solid organ tumors not responsive to currently available treatments. The secondary objective of the study is to monitor the tumor response to this form of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: January 2006
• Est. primary completion date: January 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have solid organ tumors refractory to currently available treatments.

• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

• Have a life expectancy of 4 months

• Have normal organ and bone marrow function

Exclusion Criteria:

• Have had biologic, hormonal, anti-neoplastic chemotherapy, or radiation therapy within 4 weeks prior to the 1st dose of the study drug or those who have not recovered from adverse events from agents administered more than 4 weeks earlier.

• Use of investigational agent in the 4 weeks prior to 1st dose of the study drug

• Use of immunosuppressive therapy in the 4 weeks prior to the 1st dose

• Have a history of, or clinical evidence of, myocardial ischemia, congestive heart failure, or myocardial arrhythmias requiring treatment within the past 6 months

• Have uncontrolled intercurrent or chronic illness, but not limited to, ongoing or active infection such as hepatitis B or C, immune dysfunction such as autoimmune disease, endocrine dysfunction such as hypo- or hyperthyroidism, psychiatric illness such as depression or suicidal tendency or social situations that would limit compliance with study requirements

• Have a history of disease requiring ongoing steroid treatment

• Have a history of seizure disorders uncontrolled on medication

• Have a history of clinically significant coagulation or bleeding disorders or abnormalities

• Are HIV positive. HIV positive subjects are excluded from the study because of possible interactions with the immunomodulatory effects of 852A and because of potential pharmacokinetic interactions associated with combination retroviral therapy.

• Are pregnant or lactating

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• 852A

Locations

Country	Name	City	State
United States	University of Minnesota	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Pharmacokinetics
Secondary	Tumor Response